Adriana Rossi, MD, assistant professor of medicine, director of CART and the Stem Cell Transplant Clinical Service at the Center of Excellence for Multiple Myeloma, Mount Sinai, New York, discusses the role a care partner may play when a family member or friend is undergoing CAR T-cell therapy. Dr Rossi describes the use of CAR T-cell therapy in multiple myeloma and how it may fit into a treatment plan.
Tara K. Gregory, MD, Colorado Blood Cancer Institute, Denver, Colorado, discusses CAR T-cell therapy for multiple myeloma. Dr Gregory reviews steps involved in CAR T-cell therapy, potential outcomes…
Patrick Connor Johnson, MD, Massachusetts General Hospital, Boston, Massachusetts, discusses real-world outcomes following treatment with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Dr Johnson notes the…
Rahul Banerjee, MD, assistant professor, Clinical Research Division, University of Washington Fred Hutchinson Cancer Center, Seattle, Washington, discusses the challenges facing CAR T-cell therapy in multiple myeloma. Dr…
Manali Kamdar, MD, clinical director of lymphoma services, University of Colorado Cancer Center, Denver, Colorado, discusses the use of circulating tumor DNA as an early predictor of outcomes…
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses findings from one arm of the Phase 2 KarMMA-2 trial that was designed to investigate idecabtagene vicleucel in…
Krina K. Patel, MD, MSc, associate professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses results from a recent study of real-world…
Michael Wang, MD, professor, Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses results from the TRANSCEND-NHL-001 study, which was designed to investigate…
Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Teri Foy, PhD, Senior Vice President, Cancer Immunology and Cell Therapy Thematic Research Center and Seattle site lead, and Mike Burgess, MD, PhD, Senior Vice President, Head of…
Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
